Aprea Therapeutics (NASDAQ:APRE) Trading 8.4% Higher

Aprea Therapeutics (NASDAQ:APRE) shares traded up 8.4% during mid-day trading on Thursday . The company traded as high as $27.14 and last traded at $26.07. 130,249 shares changed hands during trading, an increase of 24% from the average session volume of 104,625 shares. The stock had previously closed at $24.06.

A number of analysts have recently issued reports on the company. Zacks Investment Research downgraded Aprea Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 24th. Royal Bank of Canada reiterated a “buy” rating and set a $42.00 price target on shares of Aprea Therapeutics in a research report on Thursday, June 11th. JPMorgan Chase & Co. initiated coverage on Aprea Therapeutics in a report on Tuesday. They set a “neutral” rating on the stock. HC Wainwright reissued a “hold” rating and set a $30.00 price objective on shares of Aprea Therapeutics in a report on Wednesday, August 12th. Finally, BidaskClub raised Aprea Therapeutics from a “strong sell” rating to a “sell” rating in a report on Tuesday, September 15th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. Aprea Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $34.67.

The stock has a 50 day simple moving average of $26.79 and a 200 day simple moving average of $30.88. The firm has a market capitalization of $552.35 million and a PE ratio of -3.48.

Aprea Therapeutics (NASDAQ:APRE) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.78) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.18). Analysts anticipate that Aprea Therapeutics will post -2.73 EPS for the current year.

In other news, major shareholder Kdev Investments Ab sold 241,703 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $34.55, for a total transaction of $8,350,838.65. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 52.20% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in APRE. Meeder Asset Management Inc. bought a new position in shares of Aprea Therapeutics during the first quarter valued at $39,000. Great West Life Assurance Co. Can purchased a new stake in shares of Aprea Therapeutics during the second quarter worth $48,000. Citigroup Inc. increased its position in shares of Aprea Therapeutics by 48.7% during the first quarter. Citigroup Inc. now owns 1,924 shares of the company’s stock worth $67,000 after acquiring an additional 630 shares during the period. PNC Financial Services Group Inc. purchased a new position in Aprea Therapeutics in the second quarter valued at $78,000. Finally, JPMorgan Chase & Co. increased its holdings in Aprea Therapeutics by 47.6% in the first quarter. JPMorgan Chase & Co. now owns 3,108 shares of the company’s stock valued at $108,000 after buying an additional 1,003 shares during the last quarter. Institutional investors own 77.63% of the company’s stock.

Aprea Therapeutics Company Profile (NASDAQ:APRE)

Aprea Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The company's lead drug candidate APR-246, a small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies.

See Also: Most Volatile Stocks

Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.